We read with interest the article by Dr Montorsi and colleages 1 regarding the current status of local penile therapy. We agree with the authors' closing statement that topical agents remain an attractive option if an effective system is found, which facilitates permeation of skin and tunica albuginea. Recently we had the opportunity to explore the efficacy and safety of a new agent for topical penile therapy, prostaglandin E 1 ethyl ester (PGE 1 -EE). PGE 1 -EE is a prodrug of PGE 1 with an improved transdermal permeation due to the esterification. 2 Here we want to report the first experiences with this new therapeutical route. In our open monocenter pilot study 17 men with more than 6 months' history of erectile dysfunction (ED) of organic or psychogenic origin were enrolled. Our patients had a mean erectile function score of 12 measured by the erectile function (EF) domain of the international index of erectile function (IIEF). 3 For topical treatment a patch containing PGE 1 -EE in the adhesive (3 mg=cm 2 ) was applied to the shaft of the penis. In a titration period patients received increasing doses of PGE 1 -EE (30, 60, 120 mg) at the trial site in intervals of at least 6 days until an appropriate dose had been detected or until the highest dose had been reached. Patches were applied until complete erection (maximum 3.5 h). Local tolerability and efficacy were assessed judging an erection sufficient for sexual intercourse ( 4 on a 1 -5 scale) as response. In a second treatment period patients applied patches of the most appropriate or highest dose at home twice.
Sixteen patients completed the titration period up to the maximum dose of 120 mg, 13 patients completed the home treatment period. Erectile response increased dose-dependently during the titration period. The mean erection score for the maximum dose of 120 mg PGE 1 -EE was 3.06 (1 -5 scale). With this dose six of the 16 patients (37.5%) achieved erections that were judged sufficient for vaginal penetration (score 4; Table 1 ). For responders the mean duration of erection was 19 min. Thirteen patients entered the home treatment period, all of them ultimately using the 120 mg dose. Four of these patients (30.8%) were classified as responders after at least one of the two applications led to sexual intercourse.
Local tolerability as assessed by the investigator using symptom scores was very good. Irritations were limited to transient erythema and oedema at the application site due to the vasodilative effect of PGE 1 -EE. They were generally graded as 'very slight (barely perceptible)' (score 1), the maximum score was 'well defined' (score 2) both for erythema and oedema (0 -4 scale in both cases). Two patients reported evident burning of the penile skin (score 2 on a 0 -3 scale). None of the 17 men who entered the study withdrew because of adverse events.
With regard to the low dosage used in this study the response was satisfactory not only at the trial site but also during the home treatment period. Recently two other studies using a topically applied PGE 1 gel formulation with a transdermal permeation enhancer (SEPA 1 ) have also shown efficacy in the treatment of ED. 4, 5 However, both were in-office trials without a home treatment assessment.
An advantage of PGE 1 -EE is the improved transdermal permeation without additional enhancing agents, which tend to cause evident local irritation. The lipophilic ethyl ester of PGE 1 -EE serves as a vehicle. During transdermal permeation more than 99% of PGE 1 -EE is metabolized by ubiquitous esterases, leading to resorption of the active ingredient PGE 1 and its metabolites by the capillaries. 6 We believe that this new drug delivery system has the potential to play a role in local penile therapy.
Further evaluation of this route is in progress using higher doses of PGE 1 -EE in a placebo-controlled trial. 
